Abstract
Ginsenosides, the main active constituents of Panax ginseng Meyer (P. ginseng), have potential therapeutic effects. All tested ginsenosides except ginsenoside F1 have previously been reported in inflammation studies using the RAW 264.7 macrophage cell line. We examined the anti-inflammatory effects of single sugar moiety ginsenosides such as compound K (CK), Rh2, Rh1, and F1 that were isolated from P. ginseng through in silico docking studies. We investigated their biological activity predictions, including absorption, distribution, metabolism, excretion, and toxicity and PASS properties, on the suppression of NF-κB, followed by in vitro validation in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophage cells. The molecular docking results of our study showed that all treated ginsenosides are non-toxic and may be drug-like molecules. The molecular binding interactions of these ginsenosides with the active residues of NF-κB noticeably support their anti-inflammatory activity. CK and Rh1 significantly reduced the production of nitric oxide, cyclooxygenase-2 (COX-2), and pro-inflammatory cytokines such as prostaglandin E2 and tumor necrosis factor alpha (TNF-α) in a dose-dependent manner. Real-time PCR and Western blot analyses further confirmed that protopanaxadiols (PPDs) and protopanaxatriols (PPTs) inhibitory effects may have been due to the down-regulation of TNF-α, inducible nitric oxide synthase, COX2, nuclear factor kappa B (NF-κB), and I kappa B kinase. The expression of co-stimulatory molecules such as ROS was also inhibited by CK and Rh1 in a dose-dependent manner. Furthermore, activation of NF-κB in LPS-stimulated RAW 264.7 macrophages was significantly suppressed by CK and Rh1. Taken together, these results provide evidence that PPD- and PPT-type ginsenosides including CK and Rh1 may exhibit strong anti-inflammatory effects by inhibiting pro-inflammatory mediators through down-regulation of NF-κB.
Similar content being viewed by others
References
Baldwin AS Jr (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649–683
Chen YQ, Ghosh S, Ghosh G (1998) A novel DNA recognition mode by the NF-kappa B p65 homodimer. Nat Struct Biol 5:67–73
Yamamoto Y, Gaynor RB (2004) I kappa B kinases: key regulators of the NF-kappa B pathway. Trends Biochem Sci 29:72–79
Laskin DL, Pendino KJ (1995) Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol 35:655–677
Guzik TJ, Korbut R, Adamek-Guzik T (2003) Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54:469–487
Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13:85–94
Zhang G, Ghosh S (2001) Toll-like receptor-mediated NF-kappa B activation: a phylogenetically conserved paradigm in innate immunity. J Clin Investig 107:13–19
Xie QW, Kashiwabara Y, Nathan C (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269:4705–4708
Barnes PJ, Karin M (1997) Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066–1071
Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annu Rev Immunol 18:621–663
De Bosscher K, Vanden Berghe W, Vermeulen L et al (2000) Glucocorticoids repress NF-kappa B-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 97:3919–3924
Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Investig 107:135–142
Pan MH, Lai CS, Dushenkov S et al (2009) Modulation of inflammatory genes by natural dietary bioactive compounds. J Agric Food Chem 57:4467–4477
Bosscher KD, Berghe WV, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24:488–522
Digital Briefs (2009) New software and websites for the chemical enterprise. Chem Eng News 87:48
Muller CW, Rey FA, Sodeoka M et al (1995) Structure of the NF-kappa B p50 homodimer bound to DNA. Nature 373:311–317
Maestro. 7.0 (2004) Schrodinger, LLC, Portland
Sterck HD (2013) Steepest descent preconditioning for nonlinear GMRES optimization. Numer Linear Algebra Appl 20:453–471
Barzilai JJ, Borwein M (1988) Two-point step size gradient methods. IMA J Numer Anal 8:141–148
Lautraite S, Bigot-Lasserre D, Bars R et al (2003) Optimization of cell based assays for medium through screening of oxidative stress. Toxicol Vitro 17:207–220
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method. Methods 25:402–408
Mohan CG, Gandhi T, Garg D et al (2007) Computer-assisted methods in chemical toxicity prediction. Mini-Rev Med Chem 7:499–507
Poroikov VV, Filimonov DA, Ihlenfeldt WD et al (2003) PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci 43:228–236
Bonizzi G, Karin M (2004) The two NF-kappa B activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280–288
Karin M, Cao Y, Greten FR et al (2002) NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–310
Jun CD, Choi BM, Kim HM et al (1995) Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages. J Immunol 154:6541–6547
Corriveau CC, Danner RL (1993) Antiendotoxin therapies for septic shock. Infect Agents Dis 1:44–52
Shapira L, Soskolne WA, Houri Y et al (1996) Protection against endotoxic shock and lipopolysaccharide induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun 64:825–828
Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216
Bao HY, Zhang J, Yeo SJ et al (2005) Memory enhancing and neuroprotective effects of selected ginsenosides. Arch Pharm Res 28:335–342
Shin YW, Bae EA, Kim DH (2006) Inhibitory effect of ginsenoside Rg5 and its metabolite ginsenoside Rh3 in an oxazolone-induced mouse chronic dermatitis model. Arch Pharm Res 29:685–690
Tawab MA, Bahr U, Karas M et al (2003) Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 31:1065–1107
Mukaida N (2000) The roles of cytokine receptors in diseases. Rinsho Byori 48:409–415
Song SB, Tung NH, Quang TH et al (2012) Inhibition of TNF-alpha-mediated NF-kappa B transcriptional activity in HepG2 cells by dammarane-type saponins from Panax ginseng leaves. J Ginseng Res 36:146–152
Tilg H, Wilmer A, Vogel W et al (1992) Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264–274
Li Q, Verma IM (2002) NF-kappa B regulation in the immune system. Nat Rev Immunol 2:725–734
Shibata W, Maeda S, Hikiba Y et al (2007) Cutting edge: the I kappa B kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 179:2681–2685
Surh YJ, Chun KS, Cha HH et al (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480–481:243–268
Acknowledgments
This work was supported by a post-doctoral fellowship grant from the Kyung Hee University in 20120351. The ginseng samples used in this study were provided by Kyung Hee University.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Ahn, S., Siddiqi, M.H., Noh, HY. et al. Anti-inflammatory activity of ginsenosides in LPS-stimulated RAW 264.7 cells. Sci. Bull. 60, 773–784 (2015). https://doi.org/10.1007/s11434-015-0773-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-015-0773-4